ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) had its price objective cut by research analysts at Guggenheim from $30.00 to $28.00 in a research note issued to investors on Monday, Benzinga reports. The brokerage presently has a "buy" rating on the stock. Guggenheim's price target would indicate a potential upside of 115.22% from the company's previous close.
A number of other research firms have also recently commented on AVBP. Weiss Ratings restated a "sell (d-)" rating on shares of ArriVent BioPharma in a research note on Thursday, October 15th. Truist Financial lifted their price objective on ArriVent BioPharma from $21.00 to $24.00 and gave the company a "buy" rating in a research note on Tuesday, November 10th. Jefferies Financial Group set a $18.00 price objective on ArriVent BioPharma in a report on Tuesday, October 6th. Wall Street Zen raised ArriVent BioPharma from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, Oppenheimer restated an "outperform" rating and set a $25.00 target price on shares of ArriVent BioPharma in a report on Monday, October 26th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, ArriVent BioPharma presently has an average rating of "Moderate Buy" and a consensus target price of $24.67.
Get Our Latest Research Report on ArriVent BioPharma
ArriVent BioPharma Price Performance
Shares of AVBP opened at $13.01 on Monday. ArriVent BioPharma has a 1-year low of $11.36 and a 1-year high of $35.83. The stock has a market cap of $672.92 million, a PE ratio of -3.61 and a beta of 1.66. The firm has a 50-day simple moving average of $21.36 and a two-hundred day simple moving average of $26.40.
ArriVent BioPharma (NASDAQ:AVBP - Get Free Report) last issued its quarterly earnings data on Monday, November 9th. The company reported ($0.81) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.24. The company had revenue of $5.00 million during the quarter, compared to analyst estimates of $0.80 million. As a group, sell-side analysts expect that ArriVent BioPharma will post -3.81 earnings per share for the current fiscal year.
Institutional Investors Weigh In On ArriVent BioPharma
Several large investors have recently bought and sold shares of AVBP. Sterling Capital Management LLC grew its position in shares of ArriVent BioPharma by 843.6% during the third quarter. Sterling Capital Management LLC now owns 1,255 shares of the company's stock worth $38,000 after buying an additional 1,122 shares in the last quarter. Quantbot Technologies LP purchased a new position in ArriVent BioPharma in the second quarter worth approximately $59,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in ArriVent BioPharma during the 3rd quarter worth approximately $76,000. Glenmede Trust Co. NA acquired a new position in ArriVent BioPharma during the 1st quarter worth approximately $209,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of ArriVent BioPharma in the 1st quarter valued at approximately $209,000. Hedge funds and other institutional investors own 9.48% of the company's stock.
ArriVent BioPharma Company Profile
(
Get Free Report)
ArriVent BioPharma is a clinical-stage biopharmaceutical company focused on developing medicines for people with cancer. The company advances therapies intended to address significant unmet medical needs, with an emphasis on treatments that may offer new options for patients with difficult-to-treat tumors. Its lead clinical program is furmonertinib, an oral targeted therapy being studied for non-small cell lung cancer with certain epidermal growth factor receptor (EGFR) mutations, including exon 20 insertion mutations.
Further Reading

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider ArriVent BioPharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ArriVent BioPharma wasn't on the list.
While ArriVent BioPharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.